Concomitant Use of DPP ‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70500 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Yusuke Koura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Oxaliplatin, Peripheral Nervous System Diseases, Dipeptidyl-Peptidase IV Inhibitors, Antineoplastic Agents. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency, Support for Pioneering Research Initiated by the Next Generation.
Abstract (Originalsprache)
Oxaliplatin‐induced peripheral neuropathy (OIPN) causes numbness and pain in the limbs, often leading to interruption of chemotherapy and representing a significant clinical problem. Previous basic studies have suggested that the dipeptidyl peptidase‐4 (DPP‐4) inhibitor alogliptin may prevent OIPN. To evaluate whether concomitant use of DPP‐4 inhibitors could prevent the development of OIPN in clinical practice, we retrospectively analyzed data from 1180 patients who initiated oxaliplatin treatment at Kyushu University Hospital between January 1, 2009 and December 31, 2019. The primary endpoint was the occurrence of OIPN of any grade. Kaplan–Meier analysis with cumulative doses demonstrated a significantly lower incidence of OIPN in the DPP‐4 inhibitor group ( p = 0.0422). After propensity score matching to adjust for patient backgrounds, the protective association remained significant ( p = 0.0389). Furthermore, Cox proportional hazards analysis incorporating gender, age, regimen, and concomitant DPP‐4 inhibitor use as covariates confirmed that DPP‐4 inhibitor use was an independent protective factor for OIPN (HR = 0.690; 95% CI, 0.490–0.972; p = 0.034). These findings suggest that concomitant use of DPP‐4 inhibitors may moderate the development of OIPN in patients receiving oxaliplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan.
ORCID-Profile: Keisuke Mine, Shunsuke Fujita, Takehiro Kawashiri, Takeshi Hirota, Mayako Uchida, Daisuke Kobayashi
Förderung
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Support for Pioneering Research Initiated by the Next Generation
Zitieren
APA
Koura, Y., Mine, K., Fujita, S., Kawashiri, T., Mori, Y., Ueda, M., Kaneko, R., Hirota, T., Uchida, M., & Kobayashi, D. (2026). Concomitant Use of DPP ‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70500
Vancouver
Koura Y, Mine K, Fujita S, Kawashiri T, Mori Y, Ueda M, et al. Concomitant Use of DPP ‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study. Clinical and Translational Science. 2026. doi:10.1111/cts.70500
BibTeX
@article{Koura2026,
author = {Koura, Yusuke and Mine, Keisuke and Fujita, Shunsuke and Kawashiri, Takehiro and Mori, Yusuke and Ueda, Mami and Kaneko, Risa and Hirota, Takeshi and Uchida, Mayako and Kobayashi, Daisuke},
title = {Concomitant Use of DPP ‐4 Inhibitors May Prevent the Development of Oxaliplatin‐Induced Peripheral Neuropathy: A Retrospective Cohort Study},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70500}
}
EUVIMED